Aarti Drugs posts Q1 FY26 PAT higher at Rs. 54 Cr
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
During Q1FY26, the company incurred Capex of ~Rs. 48.5 crores mainly towards capacity expansion, backward integration and finished formulation R&D
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
Aims to support healthcare practitioners with evidence-based cough categorization tools that enable choosing the right molecules for effective & targeted relief from cough
Plant-based chemistries have an outsized role to play for the HPC sector by meeting demand for good, gentle, and green products
This marks the fourth acquisition by Corona Remedies from multinational corporations
Enables additional US manufacturing capacity to serve increased demand for pharma/biotech customers
Godavari Biorefineries receives patent from CNIPA
New platform powered by Opentrons expands lab automation to accelerate scientific discovery
This collaboration marks a significant milestone for Abluva as the company aims to deliver value and innovative solutions in agentic AI security
Subscribe To Our Newsletter & Stay Updated